Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
A panel of advisors to the Food and Drug Administration (FDA) rejected MDMA as a treatment for post-traumatic stress disorder (PTSD) on Tuesday, citing a lack of evidence that the benefits would outweigh the risks of introducing the psychedelic treatment to patients. Most stocks in the psychedelic space took a hit on Wednesday as a result of the ruling.
The panel voted 9-2 that MDMA, when combined with talk therapy, is not effective in treating PTSD. The panel also voted 10-1 that the current benefits do not outweigh the potential risks of using the drug to treat mental issues.
Some members of the panel, like sociologist Elizabeth Joniak-Grant, pointed to allegations of misconduct in trials that could have skewed results as a reason for voting against the use of MDMA in PTSD patients, according to NPR.
Read Also: What's Going On With MindMed And Psychedelic Stocks?
美國食品和藥物管理局(FDA)的顧問小組週二拒絕將MDMA用作創傷後應激障礙(PTSD)的治療方法，稱缺乏證據證明引入致幻治療對患者的益處大於風險，這導致致幻板塊的大多數股票在星期三受到打擊。
小組以9票對2票的投票結果認爲，MDMA與談話療法相結合不能有效地治療PTSD。小組還以10票對1票的投票結果認爲，目前的益處不足以抵消使用該藥治療心理問題的潛在風險。
據美國國家公共電臺(NPR)報道，審查小組的一些成員，如社會學家伊麗莎白·喬尼亞克·格蘭特(Elizabeth Joniak-Grant)，指責試驗中的不端行爲可能是反對將MDMA用於治療PTSD患者的原因之一。
閱讀也可以看看MindMed和致幻藥股票的最新動態
Market Movers: Many stocks in the psychedelic space traded lower Wednesday following the ruling. Cybin Inc (NYSEAMERICAN:CYBN), which develops drugs and treatments derived from psychedelic substances like psilocybin, was down by more than 10% Wednesday afternoon.
Mind Medicine (NASDAQ:MNMD), another biotech using psychedelic substances as a derivative for its treatments, traded lower by more than 8% Wednesday. ATAI Life Sciences (NASDAQ:ATAI) opened Wednesday's trading session down more than 14% from its closing price Tuesday, but was able to recover some of its losses throughout Wednesday's session, and last traded down around 6%.
The AdvisorShares Psychedelics ETF (NYSE:PSIL), a fund that tracks many publicly traded psych stocks, traded around 6% lower Wednesday afternoon.
星期三，致幻板塊的許多股票在裁決後交易低迷。開發源自致幻物質如哌醋甲酸的藥物和治療方法的Cybin Inc (NYSEAMERICAN:CYBN)週三下午下跌超過10%。
另一家生物技術公司Mind Medicine (NASDAQ:MNMD)在週三下跌超過8%。ATAI Life Sciences (NASDAQ:ATAI)的開盤價比周二收盤價下跌超過14%，但在週三交易中逐漸恢復了一些損失，最後交易價格下跌約6%。
AdvisorShares Psychedelics ETF (NYSE:PSIL)是一支跟蹤許多公開交易的致幻藥股票的基金，在週三下午交易下跌約6%。
What's Next: While the FDA does not have to follow that advisory board's recommendation, the ruling was seen throughout the industry as a blow to the progress made in approving and regulating treatments that utilize psychedelics. Proponents of psych drugs argue that many show more effectiveness than mental health treatments currently available on the market.
雖然美國食品和藥物管理局不必遵循諮詢委員會的建議，但行業內普遍認爲這一裁決對批准和管理利用致幻藥進行治療的進展構成打擊。致幻藥的倡導者認爲，許多致幻藥比目前市場上的心理健康治療方法更有效。
Now Read: Nvidia Has 'Multi-Year Lead' On AMD, Intel: Bank Of America Analyst Expects Stock To Hit $1,500 Per Share
現在閱讀:美銀分析師預計，英偉達股價將達到1,500美元，並且擁有對AMD和英特爾的多年領先地位
Photo: Shutterstock
Photo: shutterstock
譯文內容由第三人軟體翻譯。